Back to Agenda
Session 10 Track 2: Along the Path of Drug Approval; A Hodgepodge of IDMP, EMA Support for SMEs, and ICH M11 CeSHarP
Session Chair(s)
Michiel Stam
Management Consultant, MAIN5 Gmbh & Co. Kgaa, Germany
During this session, presenters will cover a variety of different topics. From a discussion on importance of semantics for IDMP to the benefits of getting EMA’s SME support, and an overview of the ICH M11 Clinical electronic Structured Harmonized Protocol (CeSHarP) initiative. These seemingly unrelated topics share one common goal; efficient, consistent, and reliable exchange of information sponsors and regulators to promote innovation and development of new medicines.
Learning Objective : - Assess the impact of semantics on IDMP useability
- Describe the latest developments on ICH M11 guideline, protocol template and technical specification
- Describe the Standards Development Organization (SDO) engagement process to enable electronic information exchange
- Understand how US SMEs can benefit from the EMA SME status and what the advantages are
Speaker(s)
Matthias Sijtstra
Senior Consultant, Main5 GmbH & Co. KGaA, Netherlands
EMA's Approach to Support Innovations Coming from Small- and Medium Sized Enterprises
Hans van Bruggen, MSc
Director of Regulatory Affairs, Celegence, United States
IDMP is about semantics
Vivian Combs, MS
Executive Director, Clinical Trial Foundations, Eli Lilly and Company, United States
ICH M11 Clinical electronic Structured Harmonized Protocol (CeSHarP): Enabling Consistency and Information Exchange
Have an account?